Heart Test Laboratories (NASDAQ:HSCS) Price Target Lowered to $14.00 at Ascendiant Capital Markets

Heart Test Laboratories (NASDAQ:HSCS) had its price target cut by analysts at Ascendiant Capital Markets from $15.00 to $14.00 in a report issued on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Ascendiant Capital Markets’ target price would indicate a potential upside of 359.02% from the stock’s previous close.

Separately, Maxim Group reaffirmed a “buy” rating and set a $12.00 price target on shares of Heart Test Laboratories in a report on Wednesday, December 18th.

Heart Test Laboratories Trading Up 4.1 %

Shares of Heart Test Laboratories stock opened at $3.05 on Tuesday. The stock has a market capitalization of $2.99 million, a PE ratio of -0.39 and a beta of 2.77. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.72 and a quick ratio of 1.52. The company’s fifty day simple moving average is $3.44 and its 200-day simple moving average is $3.43. Heart Test Laboratories has a 1-year low of $2.36 and a 1-year high of $13.50.

Heart Test Laboratories (NASDAQ:HSCS) last posted its quarterly earnings data on Thursday, March 13th. The company reported ($2.57) EPS for the quarter, missing the consensus estimate of ($2.53) by ($0.04). As a group, equities analysts anticipate that Heart Test Laboratories will post -10.01 earnings per share for the current year.

Heart Test Laboratories Company Profile

Heart Test Laboratories, Inc, a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals.